

1 **SARS-CoV-2 susceptibility of cell lines and substrates commonly used in diagnosis and**
2 **isolation of influenza and other viruses**

3 Li Wang, Xiaoyu Fan, Gaston Bonenfant, Dan Cui, Jaber Hossain, Nannan Jiang, Gloria
4 Larson, Michael Currier, Jimma Liddell, Malania Wilson, Azaibi Tamin, Jennifer Harcourt,
5 Jessica Ciomperlik-Patton, Hong Pang, Naomi Dybdahl-Sissoko, Ray Campagnoli, Pei-Yong
6 Shi, John Barnes, Natalie J. Thornburg, David E. Wentworth, Bin Zhou

7

8 **Affiliations:**

9 Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L. Wang, X. Fan, J.
10 Hossain, M. Currier, M. Wilson, A. Tamin, J. Harcourt, J. Ciomperlik-Patton, H. Pang, N.
11 Dybdahl-Sissoko, R. Campagnoli, J. Barnes, N. Thornburg, D.E. Wentworth, B. Zhou)

12 Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA (G. Bonenfant, N.
13 Jiang, G. Larson)

14 Battelle Memorial Institute, Atlanta, Georgia, USA (D. Cui, J. Liddell)

15 University of Texas Medical Branch, Galveston, Texas, USA (P.-Y. Shi)

16

17

18

19 Correspondence: Bin Zhou, bzhou@cdc.gov

20

21

22 **Abstract**

23 Coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other
24 viruses is inevitable as the COVID-19 pandemic continues. This study aimed to evaluate cell lines
25 commonly used in virus diagnosis and isolation for their susceptibility to SARS-CoV-2. While
26 multiple kidney cell lines from monkeys were susceptible and permissive to SARS-CoV-2, many
27 cell types derived from human, dog, mink, cat, mouse, or chicken were not. Analysis of MDCK
28 cells, which are most commonly used for surveillance and study of influenza viruses,
29 demonstrated that they were insusceptible to SARS-CoV-2 and that the cellular barrier to
30 productive infection was due to low expression level of the angiotensin converting enzyme 2
31 (ACE2) receptor and lower receptor affinity to SARS-CoV-2 spike, which could be overcome by
32 over-expression of canine ACE2 in trans. Moreover, SARS-CoV-2 cell tropism did not appear to
33 be affected by a D614G mutation in the spike protein.

34

35 INTRODUCTION:

36 Coronavirus Disease 2019 (COVID-19) has resulted in more than 70 million laboratory confirmed
37 cases and more than 1.6 million deaths in less than a year since the first case was confirmed.
38 Coinfection with SARS-CoV-2 and other viruses, such as influenza virus, has been reported (1-
39 4). As cases of COVID-19 continue to climb sharply, more coinfections are expected, especially
40 in the current and future influenza seasons.

41 Isolation and propagation of virus from clinical specimens in cell cultures or embryonated chicken
42 eggs are widely used for virus diagnosis and vaccine production, mostly under biosafety level 2
43 (BSL2) containment. Currently, SARS-CoV-2 should only be isolated and propagated under BSL3
44 containment due to its risk to laboratorians and the general public. Therefore, if any of these cell
45 lines or eggs support productive replication of SARS-CoV-2, then a validated procedure should
46 be implemented to rule out the presence of SARS-CoV-2 in the specimens prior to their
47 inoculation. However, adding a diagnostic step specific to SARS-CoV-2 in many circumstances
48 is impractical or substantially increases the cost and labor required.

49 We conducted the present study to determine whether cell lines and eggs commonly used for
50 isolation and propagation of influenza virus, poliovirus and other human viruses can support
51 productive replication of SARS-CoV-2. If a substrate is confirmed to be insusceptible to SARS-
52 CoV-2, modification of procedures for diagnosis and isolation of susceptible viruses in that
53 substrate may be unnecessary. While all results were repeated under the same or slightly different
54 conditions, some of our results were further confirmed using two divergent SARS-CoV-2 strains,
55 with multiple assay methods, and in cell lines from different sources.

56 Our study provides important information on the risk of inadvertent propagation of SARS-CoV-2
57 in cell lines and/or substrates when conducting diagnosis, isolation, propagation, or vaccine
58 production of other viruses.

59

60 MATERIALS AND METHODS

61 Viruses

62 SARS-CoV-2/USA-WA1/2020 (USA-WA1) was isolated from the specimen of the first confirmed
63 case in the United States as described previously (5). SARS-CoV-2/Massachusetts/VPT1/2020
64 (MA/VPT1) was isolated in Vero E6 cells from a nasopharyngeal specimen collected in April 2020.
65 The recombinant fluorescent reporter virus icSARS-CoV-2-mNG was generated as described
66 previously (6). The spike gene of all working stocks was sequenced. While USA-WA1 and
67 MA/VPT1 did not have mutations or variations (at 20% cut off level), icSARS-CoV-2-mNG
68 acquired a 5-residue insertion at the furin cleavage site resulting in a sequence change from
69 “PRRARS” to “PRRNIGERARS” in majority of the viral population.

70 Cells

71 MDCK-Atlanta, MDCK-London, and MDCK-SIAT1 cells were obtained from the International
72 Reagent Resources (IRR). MDCK-hCK cells were kindly provided by Y. Kawaoka (University of
73 Wisconsin-Madison). MDCK-NBL2, Vero E6, CV-1, A549, CRFK, Mv1Lu, RD, Hep-2c, HeLa, and
74 L20B cells were obtained from American Type Culture Collection (ATCC) or maintained at CDC's
75 Division of Scientific Resources. Chicken embryo fibroblasts (CEF) were obtained from Charles

76 River Laboratories (Wilmington, MA). All 25 cell lines listed in Table 1 were obtained from Quidel
77 Corporation (San Diego, CA) in pre-seeded 24-well plates except for CRFK and RhMK cells,
78 which were obtained in T-75 flasks and seeded into 24-well plates in the lab one day prior to
79 infection.

80 **Virus Infection of cell lines**

81 Cells were seeded in 6-, 12-, or 24-well plates a day prior to infection or used directly upon receipt
82 from a commercial source (Quidel). Infection dose for each experiment is specified in the results
83 section or figure legends. Infection temperature was always 37°C. In general, inoculum was saved
84 for back titration and the result was shown as 0 hours post inoculation (hpi) in some figures. Cells
85 were then washed at 1-2 hpi and supernatants or cell lysates were collected daily for at least 3
86 days and up to 5 days for infectious virus titration and for viral RNA quantification, respectively.
87 Cytopathic effect (CPE) and fluorescence signals (for icSARS-CoV-2-mNG) were observed daily.

88 **Virus infection of embryonated chicken eggs**

89 Specific-pathogen-free (SPF) embryonated chicken eggs were obtained from Charles River
90 Laboratories (North Franklin, CT, USA). USA-WA1 was inoculated into the allantoic cavity of 24
91 8- to 12-day-old eggs at 10^5 TCID₅₀/egg and incubated at 37°C for 3 days. Allantoic fluid was
92 collected from individual eggs separately as E1 samples. One hundred µl of each E1 sample was
93 passaged into a corresponding egg and 24 E2 samples were collected after 3 days of incubation.
94 Similarly, 24 E3 samples were generated from passage of E2 samples in 24 eggs. All E1, E2, and
95 E3 samples, as well as samples from cell lines, were titrated by TCID₅₀ assay and viral RNAs
96 were quantified by real-time reverse transcription PCR (rRT-PCR) assay (7). Synthetic RNA was
97 used in the rRT-PCR assay to generate the standard curve for absolute quantification.

98 **Immunoblot detection of ACE2**

99 Cells were lysed in NP-40 lysis buffer and protein concentrations were determined using a BCA
100 protein assay kit (Pierce). Cell lysates and recombinant ACE2 protein control (Sino Biological)
101 were immunoblotted for ACE2 and β-actin using primary antibodies (1:500 polyclonal goat anti-
102 human ACE2, R&D Systems, AF933; 1:1000 monoclonal mouse anti-β-Actin, Abcam, AB8226)
103 followed by secondary antibodies (1:4000 donkey anti-goat, Abcam; 1:4000 goat anti-mouse,
104 Biorad). Immunoblots were developed using SuperSignal West Pico PLUS Chemiluminescent
105 Substrate (ThermoFisher).

106 **Expression of recombinant ACE2 proteins**

107 The Expi293 Expression system (ThermoFisher) was used for production of histidine-tagged
108 ACE2 (ectodomain) proteins. The Expi293F cells were transfected with pCAGGS-ACE2
109 mammalian expression construct and cultured at 37°C with 8% CO₂ at a shaking speed of 125
110 RPM. The supernatant was harvested on day 5 and ACE2 protein was purified using HisTrap FF
111 column (GE Life Sciences), followed by desalting. The purified protein was further concentrated
112 on Amicon Ultra Centrifugal Filters with 50 KDa cutoff (Sigma-Aldrich).

113 **Bio-layer interferometry assay**

114 Affinity between SARS-CoV-2 S1 (Sino Biological, 40591-V02H) and human ACE2 (hACE2) or
115 canine ACE2 (cACE2) were evaluated using Octet RED96 instrument at 30°C with a shaking
116 speed of 1000 RPM (ForteBio). Anti-penta-His biosensors (HIS1K) (ForteBio) were used. hACE2

117 or cACE2 was loaded onto surface of biosensor at 100 nM in 10X kinetic buffer (ForteBio) for 5
118 minutes. After 1 minute of baseline equilibration, 5 minutes of association was conducted with 10-
119 100 nM of S1 to hACE2 or 25-200 nM of S1 to cACE2, followed by 5 minutes of dissociation. The
120 data were corrected by subtracting reference sample, and 1:2 (Bivalent) binding model with global
121 fit was used for determination of affinity constants.

122 **Exogenous expression of ACE2 in MDCK cells**

123 Constructs co-expressing full-length hACE2 or cACE2 with mCherry2 protein (CMV promoter-
124 ACE2-IRES-mCherry2) were generated and transfected into MDCK-SIAT1 cells via
125 electroporation with Lonza Nucleofector system (Lonza) using the manufacturer's protocol with
126 program A024. 1.5×10^6 MDCK-SIAT1 cells were transfected with 10 μ g DNA (pCMV-hACE2-
127 IRES-mCherry2, pCMV-cACE2-IRES-mCherry2, or pCMV-IRES-mCherry2 empty control). One
128 day post transfection, the cells were inoculated with USA-WA1 or icSARS-CoV-2-mNG.

129 **ACE2 Sequence alignment**

130 ACE2 protein sequences for human (NP_001358344.1), African green monkey (AAV57872.1),
131 rhesus macaque (ACI04564.1), mouse (NP_001123985.1), dog (XP_005641049.1), cat
132 (NP_001034545.1), American mink (QPL12211), and chicken (XP_416822.2) were aligned using
133 MUSCLE alignment in Geneious Prime software (version 2019.2.3).

134

135 **RESULTS**

136 **Replication of SARS-CoV-2 in a large set of cell substrates from a commercial source**

137 As the prevalence of SARS-CoV-2 infection increases during the pandemic, or when social-
138 distancing restriction is relaxed in the post-pandemic era, additional coinfections with various
139 human viruses are inevitable. Therefore, we assessed 25 cell substrates commercially available
140 from Quidel (Table 1), some of which are widely used for virus diagnosis in clinical laboratories.
141 The cells were seeded in 24-well plates and inoculated with 5×10^4 TCID₅₀/well of a fluorescent
142 reporter virus in which the ORF7a gene was replaced by the mNeonGreen gene (icSARS-CoV-
143 2-mNG), allowing successful infection to be visualized by green fluorescence signal (6). Almost
144 all non-human primate cell lines in this panel were susceptible to icSARS-CoV-2-mNG infection
145 except for CV-1 cells (Figure 1). In contrast, none of the human, mouse, mink, dog, or cat cell
146 lines tested yielded fluorescent cells after infection. The Super-E Mix cells were likely susceptible
147 because this cell culture is a mixture containing BGMK cells, which were found to be susceptible
148 to SARS-CoV-2 (Figure 1). We then inoculated all these cell lines with 5×10^4 TCID₅₀/well of the
149 wild type SARS-CoV-2/USA-WA1/2020 (USA-WA1) strain and titrated supernatants collected
150 over 5 days. Consistent with the results from icSARS-CoV-2-mNG infection, all non-human
151 primate cell lines except CV-1 cells supported productive virus replication, whereas all other cell
152 lines failed to generate infectious virus (Figure 2). It should be noted that viral titers in CRFK cells
153 increased slightly at 2 dpi (Figure 2), suggesting that this cell line may support a low level of
154 replication. The results along with the cell substrates' information are summarized in Table 1.

155

156

157

158 **Replication of SARS-CoV-2 in influenza virus substrates**

159 MDCK cells and embryonated chicken eggs are widely used for influenza virus isolation and
160 propagation. There are multiple lineages or derivatives of MDCK cells used by laboratories for
161 different types or subtypes of influenza viruses. Some lineages, such as MDCK-SIAT1 and hCK
162 cells, were genetically modified and cloned from single cells, resulting in altered cell morphology
163 and enhanced susceptibility to some subtypes of influenza viruses compared to their parental
164 MDCK cell lines (8, 9). The different lineages of MDCK cells have altered gene expression profiles
165 and surface glycans, and it is unclear whether that would affect their susceptibility to SARS-CoV-
166 2. Therefore, we examined the susceptibility to SARS-CoV-2 in representative lineages of MDCK
167 cells that are used widely in different laboratories, including MDCK-NBL-2, MDCK-Atlanta, MDCK-
168 London, MDCK-SIAT1, and MDCK-hCK.

169 We inoculated Vero E6 cells (as a positive control) and various MDCK cell lines with 5×10^4
170 TCID₅₀/well of USA-WA1 and incubated for 1-2 hours at 37°C. Cells were then washed to remove
171 the inoculum, and influenza virus infection media containing TPCK-trypsin and bovine serum
172 albumin (BSA) was added to mimic the conditions used in influenza virus isolation. Supernatants
173 were collected at the indicated times post-infection and viral titers measured. Vero E6 cells
174 supported robust viral replication and reached peak titer within 2 days (Figure 3A), and infection
175 killed most cells (data not shown). In contrast, none of the five MDCK cell lines tested supported
176 SARS-CoV-2 replication. While residual infectious virus was present in some MDCK supernatant
177 samples at 2 hpi, it was below the limit of detection (LOD) by 1-day post-infection (dpi) and did
178 not cause any cytopathic effect (CPE) through 5 dpi. Similar experiments were conducted with
179 the MDCK cell lines in which the infection media contained FBS rather than BSA, and again
180 SARS-CoV-2 failed to replicate in any of the 5 MDCK cell lines (data not shown but almost
181 identical to Figure 3A).

182 Embryonated chicken eggs are another common substrate for influenza virus isolation,
183 propagation, and vaccine production. We inoculated 24 eggs each with 10^5 TCID₅₀ of USA-WA1
184 and blindly passaged the virus in eggs for 3 passages (E1, E2, and E3). Viral titers in the allantoic
185 fluid of E1, E2, and E3 eggs were below the limit of detection ($10^{1.5}$ TCID₅₀/ml) even in E1 eggs
186 (data not shown). We then used an rRT-PCR assay to quantify the viral RNA levels in the
187 inoculum and allantoic fluid samples (7). Viral RNA decreased steadily over the 3 passages in
188 eggs (Figure 3B). We also inoculated chicken embryo fibroblasts (CEF) with USA-WA1, and no
189 infectious virus was produced from the cells (Figure 3A). These results clearly demonstrate that
190 embryonated chicken eggs are not a susceptible substrate for the SARS-CoV-2 replication.

191 Collectively, the data show that substrates commonly used to culture influenza A and B viruses
192 are not susceptible to SARS-CoV-2 infection.

193 **Replication of SARS-CoV-2 in polio and enterovirus substrates**

194 From patients potentially infected with polio or enteroviruses, stool specimens are used to
195 inoculate appropriate cell lines for surveillance. As SARS-CoV-2 virus can infect multiple organs
196 and tissues and its presence in stool specimens has been reported (10-16), it is important to
197 determine if cell lines commonly used for polio and enterovirus culture could inadvertently
198 propagate SARS-CoV-2. Therefore, RD, HeLa, Hep-2C, and L20B cells were inoculated with
199 USA-WA1 at MOI of 0.1 and incubated for 2 hours after which the inoculum was removed and
200 cells were washed 3 times to remove residual virus. No CPE was observed over a 4-day period,
201 and SARS-CoV-2 was not detectable in supernatant collected at 1-4 dpi (data not shown). This

202 result was confirmed by rRT-PCR of cell lysate, which revealed that the total viral RNA levels
203 decreased compared to the inoculum, indicating that virus did not efficiently initiate RNA
204 transcription or replication (Figure 4). These results indicate that cell substrates regularly used for
205 polio and enterovirus cultures are not susceptible to SARS-CoV-2 infection when cultured under
206 these standard conditions.

207 **Replication of SARS-CoV-2 with Spike-D614G substitution**

208 During this study, we noticed that the proportion of naturally circulating virus containing a D614G
209 substitution in the spike protein was rapidly increasing. The USA-WA1 strain is an early isolate
210 that expresses spike with D614. To confirm that the cell susceptibility data obtained using this
211 virus were valid with recent strains, a subset of representative cell lines were inoculated with high
212 titer (5×10^5 TCID₅₀/well) of SARS-CoV-2/Massachusetts/VPT1/2020 (MA/VPT1), which encodes
213 a spike with G614. In selection of cell lines for the subset, we included Vero E6 cells as a cell line
214 that should support replication of MA/VPT1 given our previous findings with USA-WA1 (Figure
215 3A). Indeed, Vero E6 cells supported similar replication kinetics for MA/VPT1 as USA-WA1
216 (Figure 5A). Even with a 10-fold higher inoculum of MA/VPT1 than previously used for USA-WA1
217 tests (5×10^4 TCID₅₀/well), CV-1, A549, Mv1Lu, MDCK-NBL-2, and MDCK-SIAT1 cell lines were
218 not susceptible to this SARS-CoV-2 strain encoding spike-G614. CRFK cells inoculated with
219 MA/VPT1 generated virus titers slightly above the LOD at 1 dpi, after which titers decreased
220 (Figure 5A). Viral titers were further confirmed by rRT-PCR. Similar to the virus titer data,
221 inoculated CRFK cells had a 5-fold increase of viral RNA at 1 dpi compared to 2 hpi, but the RNA
222 levels decreased over the next two days. In contrast, CV-1, A549, Mv1Lu, MDCK-NBL-2, and
223 MDCK-SIAT1 cells did not show any noticeable increase of viral RNA levels during the time
224 course of this study (Figure 5B). All the 7 cell lines in this subset demonstrated very similar viral
225 replication kinetics for both MA/VPT1 and USA-WA1 virus strains (Figures 2-5), indicating that
226 the currently dominant virus strains with spike-G614 likely have the same cell susceptibility profile
227 as earlier strains encoding spike-D614.

228 **ACE2 as a critical determinant in susceptibility and species specificity**

229 Coronavirus spike-host receptor interactions play the major role in species specificity (17). SARS-
230 CoV-2 uses human angiotensin converting enzyme 2 (hACE2) as the host cell receptor (18).
231 Multiple species including humans, monkeys, cats, minks, ferrets, hamsters, and dogs have been
232 infected by SARS-CoV-2 in experimental and/or natural settings (19-24). To further investigate
233 the mechanism of susceptibility or resistance and gain insight into SARS-CoV-2 species
234 specificity, we analyzed the ACE2 expression levels in various cell lines. Multiple anti-ACE2
235 antibodies were screened to identify a polyclonal antibody that reacts with ACE2 from African
236 Green Monkey (Vero and CV-1), Mink (Mv1Lu), Canine (MDCK), and feline (CRFK) (data not
237 shown). Using this antibody, we determined by immunoblot that endogenous ACE2 levels were
238 very high in Vero E6 cells derived from African Green Monkey kidney but extremely low in the
239 other African green monkey kidney cell line CV-1, which could explain the drastic difference in
240 infectivity between these two cell lines. Canine ACE2 protein was not detectable in MDCK cells,
241 which surely plays a role in their resistance to SARS-CoV-2 infection. Similarly, the feline CRFK,
242 mink Mv1Lu and human A549 cells had very low or undetectable endogenous ACE2 expression
243 (Figure 6). The low protein levels of ACE2 in those cells coincided with low mRNA levels
244 determined by rRT-PCR (data not shown).

245 Since MDCK cells are the most important cell line for influenza virus isolation and propagation
246 and dogs have been infected with SARS-CoV-2, we selected canine ACE2 (cACE2) for additional
247 analysis. To better understand resistance of MDCK cells to SARS-CoV-2, constructs co-
248 expressing ACE2 protein (hACE2 or cACE2) under a CMV promoter and mCherry2 protein
249 through an IRES element were transfected into MDCK-SIAT1 cells. MDCK cells expressing
250 hACE2 (MDCK-hACE2) or cACE2 (MDCK-cACE2) as determined by mCherry2 expression were
251 efficiently infected by icSARS-CoV-2-mNG (Figure 7A). As a control, MDCK cells were also
252 transfected with an empty vector plasmid that expresses mCherry2 via the IRES element but does
253 not encode an ACE2 protein (MDCK-vector). Consistent with wild type MDCK cells the MDCK-
254 vector control cells were not susceptible to SARS-CoV-2 (Figure 7A). These results were further
255 confirmed by infecting MDCK-hACE2 and MDCK-cACE2 cells with the wild type virus USA-WA1
256 and assaying viral replication kinetics. Viral infectious titers and viral RNA levels were elevated in
257 MDCK cells overexpressing either hACE2 or cACE2 relative to MDCK-vector cells (Figure 7B and
258 7C).

259 These results indicate that the resistance of MDCK cells to SARS-CoV-2 occurs at the virus entry
260 step. Once bound, the genome is released, transcribed, translated, replicated and packaged into
261 particles that bud from infected cells fairly efficiently. However, overexpression of ACE2 in MDCK
262 cells could result in greater ACE2 expression as compared to most natural cell lines. Thus, even
263 if cACE2 does not bind the spike protein as efficiently as hACE2, overexpression could facilitate
264 entry of SARS-CoV-2 into MDCK-cACE2 cells. To determine if cACE2 binding affinity to SARS-
265 CoV-2 spike was an additional factor preventing infection of MDCK cells, we conducted bio-layer
266 interferometry (BLI) assays to compare the binding affinity of spike with cACE2 and hACE2. We
267 identified that SARS-CoV-2 spike bound to cACE2 ($KD = 19.5$ nM) 15-fold less efficiently than
268 hACE2 ($KD = 1.30$ nM) (Figure 8). The reduced binding affinity to cACE2 is likely a result of the
269 sequence differences between the hACE and cACE2 in regions directly involved in spike binding
270 (Figure 9). Thus, both low expression of cACE2 by MDCK cells and low binding affinity of cACE2
271 to SARS-CoV-2 spike contribute to the resistance of MDCK cells to SARS-CoV-2.

272

273 **DISCUSSION**

274 In this study, we determined the SARS-CoV-2 susceptibility of more than 30 cell lines or
275 derivatives and embryonated chicken eggs. This study corroborates and complements other
276 susceptibility studies published in the past few months (25, 26). For example, Barr *et al.* recently
277 showed that MDCK cells and embryonated eggs do not support productive SARS-CoV-2 infection
278 (26). The data presented here are consistent with that study, and our infectious virus titration
279 assay data further showed that SARS-CoV-2 loses infectivity rapidly in cells and eggs, while the
280 viral RNA levels decreased quite slowly. In addition, the majority of currently circulating strains
281 contain the D614G substitution in the spike protein, which could impact binding, entry, and/or
282 species specificity, and viruses with this change were not tested in previous studies. Herein, we
283 showed that the spike-D614G substitution does not alter cell susceptibility of the cell lines tested
284 including those with low levels of human (A549), non-human primate (CV-1), mink (Mv1Lu), cat
285 (CRFK), or dog (MDCK) ACE2. In the future, even in the unlikely event that other spike
286 substitutions render the binding of spike to cACE2 stronger (Fig 8), the low expression level of
287 cACE2 in MDCK cells (Figure 6) still poses a high barrier for SARS-CoV-2 to overcome. Therefore,
288 two independent studies together illustrate that MDCK cells and commonly utilized derivatives are
289 not susceptible to SARS-CoV-2 and can be safely used for influenza virus isolation, propagation,

290 and vaccine production. Additionally, chicken eggs which are used to manufacture most influenza
291 virus vaccines do not support replication of SARS-CoV-2.

292 We expanded our examination to other clinically relevant cell lines used in diagnosis and isolation
293 of a wide array of human viruses, particularly respiratory viruses (Table 1). While many of those
294 cells were tested with SARS-CoV-1 virus previously (25, 27-36), it is worth noting that cell
295 susceptibility conclusions derived from SARS-CoV-1 studies do not always apply to SARS-CoV-
296 2. For example, we and others previously showed that Mv1Lu cells supported a moderate level
297 of SARS-CoV-1 virus replication (31, 34), but they are not susceptible to SARS-CoV-2 replication
298 as demonstrated in this study. This finding could be justified by the difference in ACE2 binding
299 positions between SARS-CoV-1 and SARS-CoV-2 (37-40). Considering that mink ACE2 is only
300 83% identical to human ACE2 (Figure 9), some of the different ACE2 residues may have more
301 adverse impact on the SARS-CoV-2 entry than on the SARS-CoV-1 entry. This idea does not
302 necessarily contradict recent reports of SARS-CoV-2 infections among mink on farms (20, 41-44);
303 ACE2 expression is relatively low in Mv1Lu cells (Figure 6) but likely higher in various epithelial
304 cells *in vivo*, enabling productive infection in minks even through a weaker spike-receptor
305 interaction.

306 Overall, our study provides important information on multiple cell lines and chicken eggs regarding
307 their susceptibility to SARS-CoV-2. This study is important from a biosafety standpoint; humans
308 can be coinfecting by multiple pathogens. Specimens collected for testing and culture may contain
309 SARS-CoV-2 and these data should help laboratories avoid inadvertent propagation. The data on
310 canine ACE2 shed light on the relationship between SARS-CoV-2 susceptibility and ACE2
311 receptor affinity (species specificity) and expression level, suggesting that even ACE2 proteins
312 with a number of substitutions at key residues that contact SARS-CoV-2 spike protein can still
313 serve as functional receptors when expressed at high levels.

314

315 **Acknowledgements**

316 We thank the support and guidance from the US Centers for Disease Control and Prevention
317 COVID-19 Response Laboratory and Testing Task Force. We also thank the CDC Division of
318 Scientific Resources for providing some cell lines and other materials. This activity was reviewed
319 by CDC and was conducted consistent with applicable federal law and CDC policy: 45 C.F.R. part
320 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.
321 The conclusions, findings, and opinions expressed by authors contributing to this journal do not
322 necessarily reflect the official position of the U.S. Department of Health and Human Services, the
323 Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated
324 institutions. Use of trade names is for identification only and does not imply endorsement by the
325 Public Health Service or by the U.S. Department of Health and Human Services.

326

327 **Table 1. Overview of diagnostic cell lines obtained from a commercial source (Quidel).**

Cell line	Organism	Tissue	Type/ Morphology	Virus susceptibility profile*	SARS-CoV-1 susceptible	SARS-CoV-2 susceptible
Vero	African green monkey	Kidney	Epithelial	AdV, coxsackie B, measles, mumps, rotavirus, rubella, influenza	Yes (28, 34)	Yes
Vero 76	African green monkey	Kidney	Epithelial	AdV, coxsackie B, measles, mumps, poliovirus, rotavirus, rubella, West Nile Virus	Yes (35)	Yes
BGMK	African green monkey	Kidney	Epithelial	coxsackie B, poliovirus	Yes (28)	Yes
CV-1	African green monkey	Kidney	Fibroblast	measles, mumps, rotavirus	Yes (28)	No
LLC-MK2	Rhesus macaque	Kidney	Epithelial	enterovirus, myxovirus and poxvirus groups, poliovirus type 1, rhinovirus	Yes (28)	Yes
RhMK	Rhesus macaque	Kidney	Epithelial	enteroviruses, influenza, parainfluenza	Yes (31)	Yes
A549	Human	Lung	Epithelial	AdV, influenza, measles, mumps, parainfluenza, poliovirus, RSV, rotavirus	No (28, 30, 31); Yes(36)	No
HEL	Human	Lung	Fibroblast	AdV, CMV, echovirus, HSV, poliovirus, rhinovirus	No (28, 31)	No
HeLa	Human	Cervix	Epithelial	AdV, CMV, echovirus, HSV, poliovirus, rhinovirus	No (28)	No
HeLa 229	Human	Cervix	Epithelial	AdV, CMV, echovirus, HSV, poliovirus, rhinovirus	Unknown	No
HEp2	Human	Cervix	Epithelial	AdV, coxsackie B, HSV, measles, parainfluenza, poliovirus, RSV	No (28)	No
MRC-5	Human	Lung	Fibroblast	AdV, CMV, echovirus, HSV, influenza, mumps, poliovirus, rhinovirus	No (31)	No
MRHF	Human	Foreskin	Fibroblast	AdV, CMV, echovirus, HSV, mumps, poliovirus, rhinovirus	Unknown	No
NCI-H292	Human	Lung	Epithelial	AdV, HSV, influenza A, measles virus, RSV, rhinoviruses, vaccinia virus	No (30, 33, 36)	No
RD	Human	Muscle	Spindle; multi-nucleated	AdV, echovirus, HSV, poliovirus	No (28, 32)	No
WI-38	Human	Lung	Fibroblast	AdV, CMV, echovirus, HSV, influenza, mumps, poliovirus, rhinovirus, RSV	Unknown	No
McCoy	Mouse	Unknown	Fibroblast	HSV	Unknown	No
MNA	Mouse	Nerve	Neuroblastoma	Rabies	Unknown	No
MDCK	Dog	Kidney	Epithelial	AdV, coxsackie virus, influenza, reoviruses	No (25, 28, 29, 31, 33)	No
CRFK	Cat	Kidney	Epithelial	canine parvovirus, feline calicivirus, feline panleukopenia virus, rabies virus	Yes (25)	Yes (limited)
Mv1Lu	American mink	Lung	Epithelial	CMV, influenza	Yes (31, 34)	No
H&V-Mix	CV-1 and MRC-5	Mixture	Mixture	AdV, CMV, echovirus, HSV, influenza, poliovirus type 1, SV40 virus, VZV	Unknown	No
R-Mix	Mv1Lu and A549	Mixture	Mixture	AdV, CMV, HSV, influenza, measles, mumps, poliovirus, RSV, rotavirus	Yes (31)	No
R-Mix Too	MDCK and A549	Mixture	Mixture	AdV, HSV, influenza, MPV, measles, mumps, poliovirus, RSV, rotavirus, VZV	Unknown	No
Super E-Mix	BGMK and A549	Mixture	Mixture	AdV, HSV, influenza, measles, mumps, poliovirus, RSV, rotavirus, VZV	Unknown	Yes

328

329 *Virus susceptibility profiles listed are as reported by Quidel and not verified in this study. AdV,
 330 adenovirus; CMV, cytomegalovirus; HSV, herpes simplex virus; RSV, respiratory syncytial virus;
 331 VZV, varicella zoster virus.

332

333 **FIGURE LEGENDS**

334 **Figure 1. SARS-CoV-2 infects select commercially sourced cell lines.** Cell lines were
335 inoculated with the SARS-CoV-2 reporter virus encoding mNeonGreen (icSARS-CoV-2-mNG) at
336 5×10^4 TCID₅₀/well in 24-well plates, and infected cells were identified by green fluorescence.
337 Microscopy images were captured at 24 hpi using 10X magnification. Representative images at
338 1 dpi are shown but similar results were observed through 5 dpi, and all mNeonGreen-negative
339 cell lines remained negative.

340 **Figure 2. SARS-CoV-2 viral replication kinetics vary in commercially sourced cell lines.** The
341 25 cell lines obtained from Quidel were inoculated with USA-WA1 at 5×10^4 TCID₅₀/well in 24-well
342 plates, and supernatants were harvested at the indicated times and assayed for viral replication
343 by TCID₅₀ assay. Data are mean of $n=4 \pm$ sd.

344 **Figure 3. Influenza virus substrates do not support SARS-CoV-2 infection.** (A) Vero E6,
345 MDCK-NBL-2, MDCK-Atlanta, MDCK-London, MDCK-SIAT1, MDCK-hCK, and CEF cells were
346 inoculated with USA-WA1 at 5×10^4 TCID₅₀/well in 12-well plates, and supernatant were
347 harvested and assayed for viral replication by TCID₅₀ assay. (B) USA-WA1 total viral RNA levels
348 in allantoic fluid from infected eggs were quantified by rRT-PCR using a standard curve
349 generated by synthetic RNA. Not plotted are four eggs with undetectable RNAs for E3. Data are
350 a mean of $n=3 \pm$ sd (cells) or $n=24 \pm$ sd (eggs).

351 **Figure 4. Poliovirus substrates do not support SARS-CoV-2 infection.** Total viral RNA levels
352 were determined by rRT-PCR (standard curve generated by synthetic RNA) from total RNA
353 extracted from cell lines inoculated with USA-WA1 at MOI of 0.1 in 6-well plates. The data points
354 at 1h are represented by the RNA from the inoculum while 2h and later time points are from RNA
355 extracted from cell lysates. Data are mean of $n=3 \pm$ sd.

356 **Figure 5. SARS-CoV-2 with spike-G614 infects similar cell types as SARS-CoV-2 with spike-**
357 **D614.** Vero E6, CV-1, A549, Mv1Lu, CRFK, MDCK-NBL-2, and MDCK-SIAT1 cell lines were
358 inoculated with MA/VPT1 at 5×10^5 TCID₅₀/well in 12-well plates. (A) Supernatants were collected
359 at the indicated times and viral replication kinetics determined using TCID₅₀. Total RNA was
360 extracted from cells inoculated for the indicated times and (B) total viral RNA levels were
361 determined using rRT-PCR (standard curve generated by synthetic RNA). For all, data are a
362 mean of $n=3 \pm$ sd.

363 **Figure 6. ACE2 is differentially expressed across cell lines.** Whole cell lysate from
364 uninoculated Vero E6, CV-1, A549, Mv1Lu, CRFK, MDCK-NBL-2 and MDCK-SIAT1 cell lines
365 were immunoblotted for endogenous ACE2 expression. Recombinant hACE2 (Sino Biological)
366 was used as a positive control for detection of hACE2. 20 μ g of cell lysates or 0.2 ng of
367 recombinant hACE2 protein were loaded. β -actin was also immunoblotted from samples as a
368 loading control.

369 **Figure 7. Overexpression of cACE2 permits SARS-CoV-2 infection of MDCK cells.** (A)
370 MDCK cells transiently overexpressing an empty vector control (MDCK-vector), hACE2 (MDCK-
371 hACE2) or cACE2 (MDCK-cACE2) were mock-inoculated or inoculated with icSARS-CoV-2-mNG
372 reporter virus at 5×10^5 TCID₅₀/well in 12-well plates, and viral infection detected by fluorescent
373 microscopy. CPE was also imaged in inoculated cells. Representative images at 1 dpi are shown.
374 (B-C) MDCK-vector, MDCK-hACE2, and MDCK-cACE2 cells were inoculated with USA-WA1 at

375 5×10^5 TCID₅₀/well in 12-well plates. Supernatants were collected at the indicated times and (B)
376 viral titers determined by TCID₅₀ assay. Total RNA was extracted from cell lines inoculated for the
377 indicated length of time and (C) total viral RNA were determined using rRT-PCR (standard curve
378 generated by synthetic RNA). Data for (B-C) are a mean of $n=3 \pm$ sd.

379 **Figure 8. Canine ACE2 has lower affinity to SARS-CoV-2 spike protein compared to human**
380 **ACE2.** Bio-layer interferometry assay was used to determine the equilibrium dissociation constant
381 (KD) of hACE2 or cACE2 protein with SARS-CoV-2 spike protein. hACE2 or cACE2 recombinant
382 protein was loaded onto surface of biosensor at 100 nM and association was conducted at 10-
383 100 nM of S1-Fc for hACE2 and 25-200 nM of S1-Fc for cACE2, followed by dissociation.

384 **Figure 9. ACE2 protein sequences vary across species.** ACE2 protein sequences from human,
385 rhesus macaque, African green monkey, cat, dog, American mink, mouse, and chicken were
386 aligned using MUSCLE. Residues involved in interaction with SARS-CoV-2 spike protein (based
387 on ref (37-40)) are shown using hACE2 numbering, and residues varying from hACE2 are
388 highlighted in yellow. A gap in alignment is indicated with a dash. Percent identity to hACE2 across
389 the entire protein is shown.

390

391 **References:**

392 **Uncategorized References**

- 393 1. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 and
394 Other Respiratory Pathogens. *Jama*. 2020 Apr 15;323(20):2085-6.
- 395 2. Li ZT, Chen ZM, Chen LD, Zhan YQ, Li SQ, Cheng J, et al. Coinfection with SARS-CoV-2 and other
396 respiratory pathogens in COVID-19 patients in Guangzhou, China. *Journal of medical virology*. 2020 May
397 28.
- 398 3. Konala VM, Adapa S, Naramala S, Chenna A, Lamichhane S, Garlapati PR, et al. A Case Series of
399 Patients Coinfected With Influenza and COVID-19. *Journal of investigative medicine high impact case*
400 *reports*. 2020 Jan-Dec;8:2324709620934674.
- 401 4. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, et al. The epidemiology and clinical characteristics
402 of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. *Journal of*
403 *medical virology*. 2020 Jun 12.
- 404 5. Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, et al. Severe Acute Respiratory
405 Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. *Emerg Infect Dis*.
406 2020;26(6):1266-73.
- 407 6. Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, et al. An Infectious cDNA Clone
408 of SARS-CoV-2. *Cell Host Microbe*. 2020;27(5):841-8.e3.
- 409 7. Lu X, Wang L, Sakthivel S, Whitaker B, Murray J, Kamili S, et al. US CDC Real-Time Reverse
410 Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerging*
411 *Infectious Disease journal*. 2020;26(8):1654.
- 412 8. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the alpha-2,6-
413 sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. *J Virol*.
414 2003 Aug;77(15):8418-25.
- 415 9. Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, et al. A humanized MDCK cell line for the
416 efficient isolation and propagation of human influenza viruses. *Nat Microbiol*. 2019 Aug;4(8):1268-73.
- 417 10. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of
418 Clinical Specimens. *Jama*. 2020 Mar 11;323(18):1843-4.

- 419 11. Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, et al. Gastrointestinal Manifestations of
420 SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and
421 Meta-analysis. *Gastroenterology*. 2020 Jul;159(1):81-95.
- 422 12. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and
423 Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. *Jama*. 2020 Mar 3;323(15):1488-94.
- 424 13. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection
425 and potential evidence for persistent fecal viral shedding. *Nature medicine*. 2020 Apr;26(4):502-5.
- 426 14. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in
427 patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective
428 cohort study. *BMJ (Clinical research ed)*. 2020 Apr 21;369:m1443.
- 429 15. Tang A, Tong ZD, Wang HL, Dai YX, Li KF, Liu JN, et al. Detection of Novel Coronavirus by RT-PCR
430 in Stool Specimen from Asymptomatic Child, China. *Emerg Infect Dis*. 2020 Jun;26(6):1337-9.
- 431 16. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019
432 (COVID-19) in the United States. *Nature medicine*. 2020 Jun;26(6):861-8.
- 433 17. wentworth d. Coronavirus Binding and Entry'. *Coronaviruses: Molecular and Cellular Biology*:
434 caister academic press; 2007.
- 435 18. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a
436 SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med*.
437 2020/03/04 ed; 2020. p. 586-90.
- 438 19. Abdel-Moneim AS, Abdelwhab EM. Evidence for SARS-CoV-2 Infection of Animal Hosts.
439 *Pathogens*. 2020 Jun 30;9(7).
- 440 20. Oreshkova N, Molenaar RJ, Vreman S, Harders F, Oude Munnink BB, Hakze-van der Honing RW,
441 et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. *Euro surveillance* :
442 bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020
443 Jun;25(23).
- 444 21. Munster VJ, Feldmann F, Williamson BN, van Doremalen N, Perez-Perez L, Schulz J, et al.
445 Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. *Nature*. 2020 Sep;585(7824):268-
446 72.
- 447 22. Bosco-Lauth AM, Hartwig AE, Porter SM, Gordy PW, Nehring M, Byas AD, et al. Experimental
448 infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to
449 reexposure in cats. *Proc Natl Acad Sci U S A*. 2020 Oct 20;117(42):26382-8.
- 450 23. Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, et al. Transmission of SARS-CoV-2
451 in Domestic Cats. *N Engl J Med*. 2020 Aug 6;383(6):592-4.
- 452 24. Singla R, Mishra A, Joshi R, Jha S, Sharma AR, Upadhyay S, et al. Human animal interface of
453 SARS-CoV-2 (COVID-19) transmission: a critical appraisal of scientific evidence. *Vet Res Commun*. 2020
454 Nov;44(3-4):119-30.
- 455 25. Chu H, Chan JF, Yuen TT, Shuai H, Yuan S, Wang Y, et al. Comparative tropism, replication
456 kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical
457 manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. *Lancet*
458 *Microbe*. 2020 May;1(1):e14-e23.
- 459 26. Barr IG, Rynehart C, Whitney P, Druce J. SARS-CoV-2 does not replicate in embryonated hen's
460 eggs or in MDCK cell lines. 2020;25(25):2001122.
- 461 27. Hattermann K, Müller MA, Nitsche A, Wendt S, Donoso Mantke O, Niedrig M. Susceptibility of
462 different eukaryotic cell lines to SARS-coronavirus. *Arch Virol*. 2005;150(5):1023-31.
- 463 28. Kaye M. SARS-associated coronavirus replication in cell lines. *Emerg Infect Dis*. 2006
464 Jan;12(1):128-33.
- 465 29. Yamashita M, Yamate M, Li GM, Ikuta K. Susceptibility of human and rat neural cell lines to
466 infection by SARS-coronavirus. *Biochem Biophys Res Commun*. 2005 Aug 19;334(1):79-85.

- 467 30. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a
468 novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med*. 2003 May
469 15;348(20):1967-76.
- 470 31. Gillim-Ross L, Taylor J, Scholl DR, Ridenour J, Masters PS, Wentworth DE. Discovery of novel
471 human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-
472 specific multiplex reverse transcription-PCR. *J Clin Microbiol*. 2004 Jul;42(7):3196-206.
- 473 32. Hattermann K, Muller MA, Nitsche A, Wendt S, Donoso Mantke O, Niedrig M. Susceptibility of
474 different eukaryotic cell lines to SARS-coronavirus. *Arch Virol*. 2005 May;150(5):1023-31.
- 475 33. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus
476 associated with severe acute respiratory syndrome. *N Engl J Med*. 2003 May 15;348(20):1953-66.
- 477 34. Mossel EC, Huang C, Narayanan K, Makino S, Tesh RB, Peters CJ. Exogenous ACE2 expression
478 allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication. *J Virol*.
479 2005 Mar;79(6):3846-50.
- 480 35. Severson WE, Shindo N, Sosa M, Fletcher T, 3rd, White EL, Ananthan S, et al. Development and
481 validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a
482 100,000-compound library. *J Biomol Screen*. 2007 Feb;12(1):33-40.
- 483 36. Yen YT, Liao F, Hsiao CH, Kao CL, Chen YC, Wu-Hsieh BA. Modeling the early events of severe
484 acute respiratory syndrome coronavirus infection in vitro. *J Virol*. 2006 Mar;80(6):2684-93.
- 485 37. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by
486 full-length human ACE2. *Science*. 2020 Mar 27;367(6485):1444-8.
- 487 38. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and Functional Basis of SARS-
488 CoV-2 Entry by Using Human ACE2. *Cell*. 2020 May 14;181(4):894-904.e9.
- 489 39. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding
490 domain bound to the ACE2 receptor. *Nature*. 2020 May;581(7807):215-20.
- 491 40. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by
492 SARS-CoV-2. *Nature*. 2020 May;581(7807):221-4.
- 493 41. Enserink M. Coronavirus rips through Dutch mink farms, triggering culls. *Science*. 2020 Jun
494 12;368(6496):1169.
- 495 42. Molenaar RJ, Vreman S, Hakze-van der Honing RW, Zwart R, de Rond J, Weesendorp E, et al.
496 Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (*Neovison vison*).
497 *Veterinary pathology*. 2020 Jul 14:300985820943535.
- 498 43. Hammer AS, Quaade ML, Rasmussen TB, Fonager J, Rasmussen M, Mundbjerg K, et al. SARS-
499 CoV-2 Transmission between Mink (*Neovison vison*) and Humans, Denmark. *Emerg Infect Dis*. 2020 Nov
500 18;27(2).
- 501 44. Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, Molenaar RJ, Munger E, Molenkamp R, et al.
502 Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. *Science*.
503 2020 Nov 10.

504

Figure 1




Figure 1. SARS-CoV-2 infects select commercially sourced cell lines. Cell lines were inoculated with the SARS-CoV-2 reporter virus encoding mNeonGreen (icSARS-CoV-2-mNG) at 5×10^4 TCID₅₀/well in 24-well plates, and infected cells were identified by green fluorescence. Microscopy images were captured at 24 hpi using 10X magnification. Representative images at 1 dpi are shown but similar results were observed through 5 dpi, and all mNeonGreen-negative cell lines remained negative.

Figure 2




Figure 2. SARS-CoV-2 viral replication kinetics vary in commercially sourced cell lines. The 25 cell lines obtained from Quidel were inoculated with USA-WA1 at 5×10^4 TCID₅₀/well in 24-well plates, and supernatants were harvested at the indicated times and assayed for viral replication by TCID₅₀ assay. Data are mean of $n=4 \pm$ sd.

Figure 3




Figure 3. Influenza virus substrates do not support SARS-CoV-2 infection. (A) Vero E6, MDCK-NBL-2, MDCK-Atlanta, MDCK-London, MDCK-SIAT1, MDCK-hCK, and CEF cells were inoculated with USA-WA1 at 5×10^4 TCID₅₀/well in 12-well plates, and supernatant were harvested and assayed for viral replication by TCID₅₀ assay. (B) USA-WA1 total viral RNA levels in allantoic fluid from infected eggs were quantified by rRT-PCR using a standard curve generated by synthetic RNA. Not plotted are four eggs with undetectable RNAs for E3. Data are a mean of $n=3 \pm$ sd (cells) or $n=24 \pm$ sd (eggs).

Figure 4




Figure 4. Poliovirus substrates do not support SARS-CoV-2 infection. Total viral RNA levels were determined by rRT-PCR (standard curve generated by synthetic RNA) from total RNA extracted from cell lines inoculated with USA-WA1 at MOI of 0.1 in 6-well plates. The data points at 1h are represented by the RNA from the inoculum while 2h and later time points are from RNA extracted from cell lysates. Data are mean of $n=3 \pm$ sd.

Figure 5




Figure 5. SARS-CoV-2 with spike-G614 infects similar cell types as SARS-CoV-2 with spike-D614. Vero E6, CV-1, A549, Mv1Lu, CRFK, MDCK-NBL-2, and MDCK-SIAT1 cell lines were inoculated with MAVPT1 at 5×10^5 TCID₅₀/well in 12-well plates. (A) Supernatants were collected at the indicated times and viral replication kinetics determined using TCID₅₀. Total RNA was extracted from cells inoculated for the indicated times and (B) total viral RNA levels were determined using rRT-PCR (standard curve generated by synthetic RNA). For all, data are a mean of $n=3 \pm$ sd.

Figure 6




Figure 6. ACE2 is differentially expressed across cell lines. Whole cell lysate from uninoculated Vero E6, CV-1, A549, Mv1Lu, CRFK, MDCK-NBL-2 and MDCK-SIAT1 cell lines were immunoblotted for endogenous ACE2 expression. Recombinant hACE2 (Sino Biological) was used as a positive control for detection of hACE2. 20 μ g of cell lysates or 0.2 ng of recombinant hACE2 protein were loaded. β -actin was also immunoblotted from samples as a loading control.

Figure 7




Figure 7. Overexpression of cACE2 permits SARS-CoV-2 infection of MDCK cells. (A) MDCK cells transiently overexpressing an empty vector control (MDCK-vector), hACE2 (MDCK-hACE2) or cACE2 (MDCK-cACE2) were mock-inoculated or inoculated with icSARS-CoV-2-mNG reporter virus at 5×10^5 TCID₅₀/well in 12-well plates, and viral infection detected by fluorescent microscopy. CPE was also imaged in inoculated cells. Representative images at 1 dpi are shown. (B-C) MDCK-vector, MDCK-hACE2, and MDCK-cACE2 cells were inoculated with USA-WA1 at 5×10^5 TCID₅₀/well in 12-well plates. Supernatants were collected at the indicated times and (B) viral titers determined by TCID₅₀ assay. Total RNA was extracted from cell lines inoculated for the indicated length of time and (C) total viral RNA were determined using rRT-PCR (standard curve generated by synthetic RNA). Data for (B-C) are a mean of $n=3 \pm$ sd.

Figure 8




Figure 8. Canine ACE2 has lower affinity to SARS-CoV-2 spike protein compared to human ACE2. Bio-layer interferometry assay was used to determine the equilibrium dissociation constant (K_D) of hACE2 or cACE2 protein with SARS-CoV-2 spike protein. hACE2 or cACE2 recombinant protein was loaded onto surface of biosensor at 100 nM and association was conducted at 10-100 nM of S1-Fc for hACE2 and 25-200 nM of S1-Fc for cACE2, followed by dissociation.

Figure 9

Amino acid residue:	24	27	28	30	31	34	35	37	38	41	42	79	82	83	330	353	354	355	357	393	Protein length (aa)	% identity to human ACE2
Human	Q	T	F	D	K	H	E	E	D	Y	Q	L	M	Y	N	K	G	D	R	R	805	–
Rhesus macaque	Q	T	F	D	K	H	E	E	D	Y	Q	L	M	Y	N	K	G	D	R	R	805	95.2
African green monkey	Q	T	F	D	K	H	E	E	D	Y	Q	L	M	Y	N	K	G	D	R	R	805	94.5
Cat	L	T	F	E	K	H	E	E	E	Y	Q	L	T	Y	N	K	G	D	R	R	805	85.2
Dog	L	T	F	E	K	Y	E	E	E	Y	Q	L	T	Y	N	K	G	D	R	R	804	84.0
American mink	L	T	F	E	K	Y	E	E	E	Y	Q	H	T	Y	N	K	H	D	R	R	805	83.0
Mouse	N	T	F	N	N	Q	E	E	D	Y	Q	T	S	F	N	H	G	D	R	R	805	82.1
Chicken	–	T	F	A	E	V	R	E	D	Y	E	N	R	F	N	K	N	D	R	R	808	65.7

Figure 9. ACE2 protein sequences vary across species. ACE2 protein sequences from human, rhesus macaque, African green monkey, cat, dog, American mink, mouse, and chicken were aligned using MUSCLE. Residues involved in interaction with SARS-CoV-2 spike protein (based on ref (37-40)) are shown using hACE2 numbering, and residues varying from hACE2 are highlighted in yellow. A gap in alignment is indicated with a dash. Percent identity to hACE2 across the entire protein is shown.